# A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

> **NCT02974322** · PHASE3 · WITHDRAWN · sponsor: **Celgene**

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** GED-0301
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02974322
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12-01
- **Primary completion:** 2018-11-17
- **Final completion:** 2018-12-24
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision not to start trial
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02974322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02974322, "A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02974322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*